Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immunome, Inc. - Common Stock (NQ:IMNM)

15.69 -0.37 (-2.30%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Immunome, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Immunome Appoints Phil Roberts as Chief Technical Officer
From Immunome, Inc.
Via Business Wire
Immunome to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Immunome, Inc.
Via Business Wire
Immunome Appoints Carol A. Schafer to Board of Directors
From Immunome, Inc.
Via Business Wire
Immunome to Acquire Antibody-Related Assets and Materials from Atreca
From Immunome, Inc.
Via Business Wire
Immunome Inc. (NASDAQ: IMNM) Leading the Way in Thursday Trading Based on Percentage Gain
Via Investor Brand Network
Why Are Immunome Shares Trading Higher Today
Immunome Inc (NASDAQ: IMNM) and Morphimmune have announced a merger agreement in  
Via Benzinga
Atreca Announces Asset Purchase Agreement for Sale of Antibody-Related Assets and Materials to Immunome
From Atreca, Inc.
Via GlobeNewswire
Immunome to Present at the Stifel 2023 Healthcare Conference
From Immunome, Inc.
Via Business Wire
Immunome Reports Third Quarter 2023 Financial Results
From Immunome, Inc.
Via Business Wire
Immunome: Q1 Earnings Insights
 
Via Benzinga
Immunome Appoints Jean-Jacques Bienaimé to Board of Directors
From Immunome, Inc.
Via Business Wire
7 Biotech Stocks to Get In Now Before Investors Catch On
Biotech stocks are down, but there are hidden gems among the rubble. Get in now before the broader market finds them. 
Via InvestorPlace
Immunome Appoints Bob Lechleider, M.D., as Chief Medical Officer
From Immunome, Inc.
Via Business Wire
Immunome and Morphimmune Announce Successful Completion of Merger with $125 Million PIPE to Develop Novel Targeted Cancer Therapies
From Immunome, Inc.
Via Business Wire
Immunome Reports Second Quarter 2023 Financial Results
From Immunome, Inc.
Via Business Wire
Nasdaq Moves Lower; Acuity Brands Earnings Top Estimates
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 200 points on Thursday. The Dow traded up 0.68% to 34,081.83 while the NASDAQ fell 0.23% to 13,560.57. The S&P... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
IMNM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Immunome, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Why Franklin Covey Shares Are Trading Higher By 25%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Sigilon Therapeutics, Inc. (NASDAQ: SGTX) shares climbed 523.8% to $24.25 after Eli Lilly agreed to acquire the company for $14.92/share in cash. 
Via Benzinga
Immunome (NASDAQ: IMNM) and Morphimmune Announce Merger to Develop Best-in-Class Targeted Cancer Therapies
Via Spotlight Growth
Dow Rises Over 100 Points; US GDP Grows 2% In Q1
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 100 points on Thursday. Following the market opening Thursday, the Dow traded up 0.37% to 33,977.04 while the NASDAQ rose... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Immunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million to Develop Targeted Cancer Therapies
From Immunome
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Immunome Publishes Preclinical Research Demonstrating that Inhibition of IL-38 Using an Antibody Leads to Anti-Tumor Activity
From Immunome, Inc.
Via Business Wire
Immunome Reports First Quarter 2023 Financial Results
From Immunome, Inc.
Via Business Wire
Immunome Reports Fourth Quarter and Full Year 2022 Financial Results
From Immunome, Inc.
Via Business Wire
Immunome to Present at 13th Annual World ADC London Conference
From Immunome, Inc.
Via Business Wire
Immunome Announces Formation of Antibody-Drug Conjugate and T Cell Redirection Advisory Board
From Immunome, Inc.
Via Business Wire
AbbVie Briefly Breaks Out After Tapping Immunome In $30 Million Cancer Deal
AbbVie is tapping Immunome to help develop new cancer treatments. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.